NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Income from Continuing Operations
NAYA Biosciences Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Income from Continuing Operations
-$7.5m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Income from Continuing Operations
$1.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
4%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Income from Continuing Operations
$1.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Income from Continuing Operations
$3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Income from Continuing Operations
$13.4B
|
CAGR 3-Years
24%
|
CAGR 5-Years
30%
|
CAGR 10-Years
23%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Income from Continuing Operations
$2.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-7.5m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Income from Continuing Operations amounts to -7.5m USD.
What is NAYA Biosciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-28%
Over the last year, the Income from Continuing Operations growth was 15%. The average annual Income from Continuing Operations growth rates for NAYA Biosciences Inc have been 11% over the past three years , -28% over the past five years .
You don't have any saved screeners yet